Application Nr Approved Date Route Status External Links
NDA021357 None Intravenous None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

1 Indications And Usage Magnetic Resonance Imaging (Mri) Of The Central Nervous System (Cns) In Adults And Pediatric Patients (Including Term Neonates), To Visualize Lesions With Abnormal Blood-Brain Barrier Or Abnormal Vascularity Of The Brain, Spine, And Associated Tissues. (1.1) Magnetic Resonance Angiography (Mra) To Evaluate Adults With Known Or Suspected Renal Or Aorto-Ilio-Femoral Occlusive Vascular Disease. (1.2) 1.1 Magnetic Resonance Imaging (Mri) Of The Central Nervous System (Cns) Multihance Is Indicated For Intravenous Use In Magnetic Resonance Imaging (Mri) Of The Central Nervous System (Cns) In Adults And Pediatric Patients (Including Term Neonates), To Visualize Lesions With Abnormal Blood-Brain Barrier Or Abnormal Vascularity Of The Brain, Spine, And Associated Tissues. 1.2 Magnetic Resonance Angiography (Mra) Of Renal And Aorto-Ilio-Femoral Vessels Multihance Is Indicated For Use In Magnetic Resonance Angiography (Mra) To Evaluate Adults With Known Or Suspected Renal Or Aorto-Ilio-Femoral Occlusive Vascular Disease.

All Formulated Excipients (0 Total)

None

Active Ingredients ( 1 Total)

Name Structure ZINC ID(s)
1. Gadobenate Dimeglumine

Comments